Viatris VTRS
NASDAQ VTRS
$16.44 -0.17 (-0.99%)
As of: Sep 9, 2026 · 3:06 PM EDT

Viatris (VTRS) Non-Current Assets (2019 - 2026)

Viatris (VTRS) posted Non-Current Assets of $25.0 billion for Q2 2026, down 3.58% on a QoQ basis from $25.9 billion in Q1 2026, and down 12.74% year-over-year from $28.6 billion in Q2 2025.

Analysis

Viatris (VTRS) Non-Current Assets (2019 - 2026) Analysis & Trends

Viatris has reported Non-Current Assets for 8 years, with the latest figure at $25.0 billion in Q2 2026.

  • On a quarterly basis, Non-Current Assets fell 12.74% year-over-year to $25.0 billion in Q2 2026; TTM through Jun 2026 was $106.3 billion, a 13.53% decrease from a year earlier, with the FY2025 full-year figure at $27.4 billion, down 14.31% from the prior year.
  • Non-Current Assets was $25.0 billion for Q2 2026 at Viatris, down from $25.9 billion in the prior quarter.
  • The five-year high for Non-Current Assets was $41.7 billion in Q1 2022, with the low at $25.0 billion in Q2 2026.
  • Average Non-Current Assets over 5 years is $33.7 billion, with a median of $34.0 billion recorded in 2024.
  • The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 7877260.0% in 2022, then fell 16.38% in 2025.
  • Over 5 years, Non-Current Assets stood at $39.4 billion in 2022, then slipped by 11.88% to $34.7 billion in 2023, then fell by 7.86% to $32.0 billion in 2024, then declined by 14.31% to $27.4 billion in 2025, then fell by 8.81% to $25.0 billion in 2026.
  • The last three Non-Current Assets figures came in at $25.0 billion (Q2 2026), $25.9 billion (Q1 2026), and $27.4 billion (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Teva Pharmaceutical Industries 42.53 Bn 38.88 Bn 2.15 Bn 26.10 Bn
2 Viatris 19.14 Bn 18.25 Bn 1.46 Bn 24.99 Bn
3 Dr Reddys Laboratories 9.86 Bn 9.69 Bn 396.53 Mn 2.92 Bn
4 Amneal Pharmaceuticals 5.45 Bn 5.33 Bn 334.51 Mn 1.83 Bn
5 Bausch Health Companies 2.33 Bn 492.63 Mn 2.10 Bn 18.27 Bn
6 Alvotech 1.51 Bn 1.36 Bn 2.56 Mn 1.04 Bn
7 Ani Pharmaceuticals 1.48 Bn 1.12 Bn 165.89 Mn 668.68 Mn
8 Amphastar Pharmaceuticals 992.90 Mn 702.78 Mn 93.47 Mn 1.11 Bn
9 Fennec Pharmaceuticals 400.20 Mn 358.95 Mn 17.15 Mn 3.25 Mn
10 RedHill Biopharma 178.79 Mn 178.79 Mn - 18.82 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 24.99 Bn
Mar 31, 2026 25.92 Bn
Dec 31, 2025 27.40 Bn
Sep 30, 2025 27.97 Bn
Jun 30, 2025 28.64 Bn
Mar 31, 2025 28.85 Bn
Dec 31, 2024 31.98 Bn
Sep 30, 2024 33.45 Bn
Jun 30, 2024 33.54 Bn
Mar 31, 2024 34.42 Bn
Dec 31, 2023 34.71 Bn
Sep 30, 2023 37.81 Bn
Jun 30, 2023 38.92 Bn
Mar 31, 2023 39.66 Bn
Dec 31, 2022 39.39 Bn
Sep 30, 2022 38.17 Bn
Jun 30, 2022 39.95 Bn
Mar 31, 2022 41.72 Bn
Dec 31, 2021 500,000.00
Sep 30, 2021 44.76 Bn